Tesh Khullar, senior vice president and advisor, Flatiron Health, discusses biosimilar education for patients and providers.
Transcript
I think education around what biosimilars actually are. So, the physicians I talked to give me a great analogy that they're using biosimilars right now; because of the way these monoclonal antibodies are made, one batch of Rituxan is different right now then a batch of Rituxan, you know, made 2 years ago. So essentially you're using a biosimilar right now and as long as there's a cost incentive to use cheaper therapies, I think the consumers are going to look at it just like you look at generics. That’s what I believe is going to happen.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.